Document is current

Any future updates will be listed below

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

Crossref DOI link: https://doi.org/10.1007/s13300-020-00989-6

Published Online: 2021-01-09

Published Print: 2021-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark